# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company devel...
Updates from THIO-101 to include response rates and survival follow-upMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", th...
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NS...
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company devel...
New science for cancer therapy drives powerful value propositionExceptional measures of efficacy by lead drug THIO in Phase 2 c...